Search

Your search keyword '"Cochran, Alistair J."' showing total 643 results
Start Over Author "Cochran, Alistair J."
643 results on '"Cochran, Alistair J."'

1. Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects

Author

Escuin-Ordinas, Helena, Liu, Yining, Sun, Lu, Hugo, Willy, Dimatteo, Robert, Huang, Rong Rong, Krystofinski, Paige, Azhdam, Ariel, Lee, Jordan, Comin-Anduix, Begoña, Cochran, Alistair J, Lo, Roger S, Segura, Tatiana, Scumpia, Philip O, and Ribas, Antoni

Subjects
Biomedical and Clinical Sciences, Engineering, Biomedical Engineering, Diabetes, Regenerative Medicine, Wound Healing and Care, 5.1 Pharmaceuticals, 2.1 Biological and endogenous factors, Skin, Administration, Topical, Animals, Diabetes Mellitus, Experimental, Female, Hair Follicle, Mice, Mice, Inbred BALB C, Mice, Obese, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Regeneration, Vemurafenib, Wnt Signaling Pathway, Wound Healing, beta Catenin, General Science & Technology
Abstract

Wound healing is a multi-step process to rapidly restore the barrier function. This process is often impaired in diabetic patients resulting in chronic wounds and amputation. We previously found that paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway via topical administration of the BRAF inhibitor vemurafenib accelerates wound healing by activating keratinocyte proliferation and reepithelialization pathways in healthy mice. Herein, we investigated whether this wound healing acceleration also occurs in impaired diabetic wounds and found that topical vemurafenib not only improves wound healing in a murine diabetic wound model but unexpectedly promotes hair follicle regeneration. Hair follicles expressing Sox-9 and K15 surrounded by CD34+ stroma were found in wounds of diabetic and non-diabetic mice, and their formation can be prevented by blocking downstream MEK signaling. Thus, topically applied BRAF inhibitors may accelerate wound healing, and promote the restoration of improved skin architecture in both normal and impaired wounds.

Published
2021

2. Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II)

Author

Jakub, James W., Lowe, Michael, Howard, J. Harrison, Farma, Jeffrey M., Sarnaik, Amod, Tuttle, Todd, Neuman, Heather B., Ariyan, Charlotte E., Uppal, Abhineet, Trocha, Steve, Beasley, Georgia M., Wasif, Nabil, Bilimoria, Karl Y., Thomay, Alan A., Allred, Jacob B., Chen, Lucia, Terando, Alicia M., Wayne, Jeffrey D., Thompson, John F., Cochran, Alistair J., Sim, Myung-Shin, Elashoff, David E., Delman, Keith A., and Faries, Mark B.

Published
2022
Full Text
View/download PDF

3. A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab

Author

Nowicki, Theodore S, Berent-Maoz, Beata, Cheung-Lau, Gardenia, Huang, Rong Rong, Wang, Xiaoyan, Tsoi, Jennifer, Kaplan-Lefko, Paula, Cabrera, Paula, Tran, Justin, Pang, Jia, Macabali, Mignonette, Garcilazo, Ivan Perez, Carretero, Ignacio Baselga, Kalbasi, Anusha, Cochran, Alistair J, Grasso, Catherine S, Hu-Lieskovan, Siwen, Chmielowski, Bartosz, Comin-Anduix, Begoña, Singh, Arun, and Ribas, Antoni

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Clinical Research, Immunization, Rare Diseases, Vaccine Related, Biotechnology, Cancer, 5.2 Cellular and gene therapies, Adoptive Transfer, Adult, Animals, Antineoplastic Agents, Immunological, CTLA-4 Antigen, Cancer Vaccines, Cell Line, Tumor, Combined Modality Therapy, Dendritic Cells, Female, Gene Knock-In Techniques, Humans, Immunotherapy, Ipilimumab, Lymphocytes, Male, Mice, Middle Aged, Molecular Targeted Therapy, Neoplasms, Phenotype, Pilot Projects, Receptors, Antigen, T-Cell, Young Adult, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeTransgenic adoptive cell therapy (ACT) targeting the tumor antigen NY-ESO-1 can be effective for the treatment of sarcoma and melanoma. Preclinical models have shown that this therapy can be improved with the addition of dendritic cell (DC) vaccination and immune checkpoint blockade. We studied the safety, feasibility, and antitumor efficacy of transgenic ACT with DC vaccination, with and without CTLA-4 blockade with ipilimumab.Patients and methodsFreshly prepared autologous NY-ESO-1-specific T-cell receptor (TCR) transgenic lymphocytes were adoptively transferred together with NY-ESO-1 peptide-pulsed DC vaccination in HLA-A2.1-positive subjects alone (ESO, NCT02070406) or with ipilimumab (INY, NCT01697527) in patients with advanced sarcoma or melanoma.ResultsSix patients were enrolled in the ESO cohort, and four were enrolled in the INY cohort. Four out of six patients treated per ESO (66%), and two out of four patients treated per INY (50%) displayed evidence of tumor regression. Peripheral blood reconstitution with NY-ESO-1-specific T cells peaked within 2 weeks of ACT, indicating rapid in vivo expansion. Tracking of transgenic T cells to the tumor sites was demonstrated in on-treatment biopsies via TCR sequencing. Multiparametric mass cytometry of transgenic cells demonstrated shifting of transgenic cells from memory phenotypes to more terminally differentiated effector phenotypes over time.ConclusionsACT of fresh NY-ESO-1 transgenic T cells prepared via a short ex vivo protocol and given with DC vaccination, with or without ipilimumab, is feasible and results in transient antitumor activity, with no apparent clinical benefit of the addition of ipilimumab. Improvements are needed to maintain tumor responses.

Published
2019

4. Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma

Author

Thompson, John F., Hyngstrom, John, Caracò, Corrado, Zager, Jonathan S., Jahkola, Tiina, Bowles, Tawnya L., Pennacchioli, Elisabetta, Hoekstra, Harald J., Moncrieff, Marc, Ingvar, Christian, van Akkooi, Alexander, Sabel, Michael S., Levine, Edward A., Henderson, Michael, Dummer, Reinhard, Rossi, Carlo Riccardo, Kane, 3rd, John M., Trocha, Steven, Wright, Frances, Byrd, David R., Matter, Maurice, MacKenzie-Ross, Alastair, Kelley, Mark C., Terheyden, Patrick, Huston, Tara L., Wayne, Jeffrey D., Neuman, Heather, Smithers, B. Mark, Desai, Darius, Gershenwald, Jeffrey E., Schneebaum, Shlomo, Gesierich, Anja, Jacobs, Lisa K., Lewis, James M., O’Donoghue, Cristina, Sardi, Armando, McKinnon, J. Greg, Slingluff, Craig L., Farma, Jeffrey M., Schultz, Erwin, Scheri, Randall P., Vidal-Sicart, Sergi, Testori, Alessandro A. E., Scolyer, Richard A., Elashoff, David E., Cochran, Alistair J., and Faries, Mark B.

Published
2023
Full Text
View/download PDF

5. Immunotherapy resistance by inflammation-induced dedifferentiation

Author

Mehta, Arnav, Kim, Yeon Joo, Robert, Lidia, Tsoi, Jennifer, Comin-Anduix, Begoña, Berent-Maoz, Beata, Cochran, Alistair J, Economou, James S, Tumeh, Paul C, Puig-Saus, Cristina, and Ribas, Antoni

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Vaccine Related, Immunization, Cancer, Immunotherapy, 5.1 Pharmaceuticals, Cell Dedifferentiation, Cell Line, Tumor, Coculture Techniques, Drug Resistance, Neoplasm, Humans, Immunotherapy, Adoptive, MART-1 Antigen, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Nerve Tissue Proteins, Nevus, Pigmented, Receptors, Chimeric Antigen, Receptors, Nerve Growth Factor, Recurrence, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

A promising arsenal of targeted and immunotherapy treatments for metastatic melanoma has emerged over the last decade. With these therapies, we now face new mechanisms of tumor-acquired resistance. We report here a patient whose metastatic melanoma underwent dedifferentiation as a resistance mechanism to adoptive T-cell transfer therapy (ACT) to the MART1 antigen, a phenomenon that had been observed only in mouse studies to date. After an initial period of tumor regression, the patient presented in relapse with tumors lacking melanocytic antigens (MART1, gp100) and expressing an inflammation-induced neural crest marker (NGFR). We demonstrate using human melanoma cell lines that this resistance phenotype can be induced in vitro by treatment with MART1 T cell receptor-expressing T cells or with TNFα, and that the phenotype is reversible with withdrawal of inflammatory stimuli. This supports the hypothesis that acquired resistance to cancer immunotherapy can be mediated by inflammation-induced cancer dedifferentiation.Significance: We report a patient whose metastatic melanoma underwent inflammation-induced dedifferentiation as a resistance mechanism to ACT to the MART1 antigen. Our results suggest that future melanoma ACT protocols may benefit from the simultaneous targeting of multiple tumor antigens, modulating the inflammatory response, and inhibition of inflammatory dedifferentiation-inducing signals. Cancer Discov; 8(8); 935-43. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 899.

Published
2018

6. High response rate to PD-1 blockade in desmoplastic melanomas.

Author

Eroglu, Zeynep, Zaretsky, Jesse M, Hu-Lieskovan, Siwen, Kim, Dae Won, Algazi, Alain, Johnson, Douglas B, Liniker, Elizabeth, Ben Kong, Munhoz, Rodrigo, Rapisuwon, Suthee, Gherardini, Pier Federico, Chmielowski, Bartosz, Wang, Xiaoyan, Shintaku, I Peter, Wei, Cody, Sosman, Jeffrey A, Joseph, Richard W, Postow, Michael A, Carlino, Matteo S, Hwu, Wen-Jen, Scolyer, Richard A, Messina, Jane, Cochran, Alistair J, Long, Georgina V, and Ribas, Antoni

Subjects
CD8-Positive T-Lymphocytes, Humans, Melanoma, Neurofibromin 1, Biopsy, Immunotherapy, Retrospective Studies, Mutation, Programmed Cell Death 1 Receptor, Cell Cycle Checkpoints, B7-H1 Antigen, Genetics, Human Genome, Cancer, 2.1 Biological and endogenous factors, General Science & Technology
Abstract

Desmoplastic melanoma is a rare subtype of melanoma characterized by dense fibrous stroma, resistance to chemotherapy and a lack of actionable driver mutations, and is highly associated with ultraviolet light-induced DNA damage. We analysed sixty patients with advanced desmoplastic melanoma who had been treated with antibodies to block programmed cell death 1 (PD-1) or PD-1 ligand (PD-L1). Objective tumour responses were observed in forty-two of the sixty patients (70%; 95% confidence interval 57-81%), including nineteen patients (32%) with a complete response. Whole-exome sequencing revealed a high mutational load and frequent NF1 mutations (fourteen out of seventeen cases) in these tumours. Immunohistochemistry analysis from nineteen desmoplastic melanomas and thirteen non-desmoplastic melanomas revealed a higher percentage of PD-L1-positive cells in the tumour parenchyma in desmoplastic melanomas (P = 0.04); these cells were highly associated with increased CD8 density and PD-L1 expression in the tumour invasive margin. Therefore, patients with advanced desmoplastic melanoma derive substantial clinical benefit from PD-1 or PD-L1 immune checkpoint blockade therapy, even though desmoplastic melanoma is defined by its dense desmoplastic fibrous stroma. The benefit is likely to result from the high mutational burden and a frequent pre-existing adaptive immune response limited by PD-L1 expression.

Published
2018

7. Classification and Histopathology of Melanoma

Author

Scolyer, Richard A., Prieto, Victor G., Elder, David E., Cochran, Alistair J., Mihm, Martin C., Balch, Charles M., editor, Atkins, Michael B., editor, Garbe, Claus, editor, Gershenwald, Jeffrey E., editor, Halpern, Allan C., editor, Kirkwood, John M., editor, McArthur, Grant A., editor, Thompson, John F., editor, and Sober, Arthur J., editor

Published
2020
Full Text
View/download PDF

8. Biopsy of the Sentinel Lymph Node

Author

Faries, Mark B., Cochran, Alistair J., McLemore, Michael, Sondak, Vernon K., Wong, Sandra L., Thompson, John F., Balch, Charles M., editor, Atkins, Michael B., editor, Garbe, Claus, editor, Gershenwald, Jeffrey E., editor, Halpern, Allan C., editor, Kirkwood, John M., editor, McArthur, Grant A., editor, Thompson, John F., editor, and Sober, Arthur J., editor

Published
2020
Full Text
View/download PDF

10. Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors.

Author

Escuin-Ordinas, Helena, Li, Shuoran, Xie, Michael W, Sun, Lu, Hugo, Willy, Huang, Rong Rong, Jiao, Jing, de-Faria, Felipe Meira, Realegeno, Susan, Krystofinski, Paige, Azhdam, Ariel, Komenan, Sara Marie D, Atefi, Mohammad, Comin-Anduix, Begoña, Pellegrini, Matteo, Cochran, Alistair J, Modlin, Robert L, Herschman, Harvey R, Lo, Roger S, McBride, William H, Segura, Tatiana, and Ribas, Antoni

Subjects
Cell Line, Tumor, Keratinocytes, Skin, Animals, Mice, Inbred BALB C, Humans, Mice, Carcinoma, Squamous Cell, Skin Neoplasms, Neoplasms, Experimental, Sulfonamides, Pyridones, Pyrimidinones, Indoles, Proto-Oncogene Proteins B-raf, Mitogen-Activated Protein Kinase Kinases, Mitogen-Activated Protein Kinases, Protein Kinase Inhibitors, Carcinogens, Treatment Outcome, Administration, Topical, Incidence, Wound Healing, Cell Cycle, MAP Kinase Signaling System, Female, Carcinogenesis, Vemurafenib
Abstract

BRAF inhibitors are highly effective therapies for the treatment of BRAF(V600)-mutated melanoma, with the main toxicity being a variety of hyperproliferative skin conditions due to paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway in BRAF wild-type cells. Most of these hyperproliferative skin changes improve when a MEK inhibitor is co-administered, as it blocks paradoxical MAPK activation. Here we show how the BRAF inhibitor vemurafenib accelerates skin wound healing by inducing the proliferation and migration of human keratinocytes through extracellular signal-regulated kinase (ERK) phosphorylation and cell cycle progression. Topical treatment with vemurafenib in two wound-healing mice models accelerates cutaneous wound healing through paradoxical MAPK activation; addition of a mitogen-activated protein kinase kinase (MEK) inhibitor reverses the benefit of vemurafenib-accelerated wound healing. The same dosing regimen of topical BRAF inhibitor does not increase the incidence of cutaneous squamous cell carcinomas in mice. Therefore, topical BRAF inhibitors may have clinical applications in accelerating the healing of skin wounds.

Published
2016

11. ASO Visual Abstract: Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in MSLT-II

Author

Jakub, James W., Lowe, Michael, Harrison Howard, J., Farma, Jeffrey M., Sarnaik, Amod, Tuttle, Todd, Neuman, Heather B., Ariyan, Charlotte E., Uppal, Abhineet, Trocha, Steve, Beasley, Georgia M., Wasif, Nabil, Bilimoria, Karl Y., Thomay, Alan A., Allred, Jacob B., Chen, Lucia, Terando, Alicia M., Wayne, Jeffrey D., Thompson, John F., Cochran, Alistair J., Sim, Myunlg-Shin, Elashoff, David E., Delman, Keith A., and Faries, Mark B.

Published
2022
Full Text
View/download PDF

12. Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal Disease

Author

Uppal, Abhineet, Stern, Stacey, Thompson, John F., Foshag, Leland, Mizzollo, Nicola, Nieweg, Omgo E., Hoekstra, Harald J., Roses, Daniel F., Sondak, Vernon K., Kashani-Sabet, Mohammed, Coventry, Brendon J., Cochran, Alistair J., Fujita, Manabu, Sim-Shin, Myung, Elashoff, David, Elashoff, Robert M., and Faries, Mark B.

Published
2020
Full Text
View/download PDF

13. Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

Author

Chodon, Thinle, Comin-Anduix, Begoña, Chmielowski, Bartosz, Koya, Richard C, Wu, Zhongqi, Auerbach, Martin, Ng, Charles, Avramis, Earl, Seja, Elizabeth, Villanueva, Arturo, McCannel, Tara A, Ishiyama, Akira, Czernin, Johannes, Radu, Caius G, Wang, Xiaoyan, Gjertson, David W, Cochran, Alistair J, Cornetta, Kenneth, Wong, Deborah JL, Kaplan-Lefko, Paula, Hamid, Omid, Samlowski, Wolfram, Cohen, Peter A, Daniels, Gregory A, Mukherji, Bijay, Yang, Lili, Zack, Jerome A, Kohn, Donald B, Heath, James R, Glaspy, John A, Witte, Owen N, Baltimore, David, Economou, James S, and Ribas, Antoni

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Prevention, Clinical Research, Vaccine Related, Genetics, Biotechnology, Cancer, Gene Therapy, Immunization, 5.2 Cellular and gene therapies, 6.2 Cellular and gene therapies, Adult, Cancer Vaccines, Dendritic Cells, Female, Humans, Immunotherapy, Adoptive, MART-1 Antigen, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Peptide Fragments, Positron-Emission Tomography, Receptors, Antigen, T-Cell, T-Lymphocytes, Tomography, X-Ray Computed, Transduction, Genetic, Treatment Outcome, Vaccination, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeIt has been demonstrated that large numbers of tumor-specific T cells for adoptive cell transfer (ACT) can be manufactured by retroviral genetic engineering of autologous peripheral blood lymphocytes and expanding them over several weeks. In mouse models, this therapy is optimized when administered with dendritic cell (DC) vaccination. We developed a short 1-week manufacture protocol to determine the feasibility, safety, and antitumor efficacy of this double cell therapy.Experimental designA clinical trial (NCT00910650) adoptively transferring MART-1 T-cell receptor (TCR) transgenic lymphocytes together with MART-1 peptide-pulsed DC vaccination in HLA-A2.1 patients with metastatic melanoma. Autologous TCR transgenic cells were manufactured in 6 to 7 days using retroviral vector gene transfer, and reinfused with (n = 10) or without (n = 3) prior cryopreservation.ResultsA total of 14 patients with metastatic melanoma were enrolled and 9 of 13 treated patients (69%) showed evidence of tumor regression. Peripheral blood reconstitution with MART-1-specific T cells peaked within 2 weeks of ACT, indicating rapid in vivo expansion. Administration of freshly manufactured TCR transgenic T cells resulted in a higher persistence of MART-1-specific T cells in the blood as compared with cryopreserved. Evidence that DC vaccination could cause further in vivo expansion was only observed with ACT using noncryopreserved T cells.ConclusionDouble cell therapy with ACT of TCR-engineered T cells with a very short ex vivo manipulation and DC vaccines is feasible and results in antitumor activity, but improvements are needed to maintain tumor responses.

Published
2014

14. A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology

Author

Linden, Kenneth G, Leachman, Sancy A, Zager, Jonathan S, Jakowatz, James G, Viner, Jaye L, McLaren, Christine E, Barr, Ronald J, Carpenter, Philip M, Chen, Wen-Pin, Elmets, Craig A, Tangrea, Joseph A, Lim, Sung-Jig, Cochran, Alistair J, and Meyskens, Frank L

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Clinical Research, Cancer, 6.1 Pharmaceuticals, Adult, Anticholesteremic Agents, Biomarkers, Tumor, Cell Transformation, Neoplastic, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Lovastatin, Male, Melanoma, Middle Aged, Nevus, Placebos, Skin Neoplasms, Oncology and Carcinogenesis, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

On the basis of large cardiovascular clinical trials of lipid-lowering agents that showed a considerable decrease in the incidence of primary melanomas in the active agent arm, we have carried out a randomized, double-blind clinical trial examining the impact of lovastatin on various biomarkers of melanoma pathogenesis. Subjects with at least two clinically atypical nevi were randomized to receive oral lovastatin or placebo for a 6-month period. Clinical, histopathologic, and molecular biomarkers were evaluated for change in the two groups. Eighty subjects were randomized, evaluable, and included in the analyses. Lovastatin showed no benefit in comparison with placebo in the primary endpoint of decreasing the level of histopathologic atypia, nor in any of the secondary endpoints of decreasing clinical atypia, impact on nevus number, nor in showing significant changes in any of the molecular biomarkers. There were no significant differences in adverse event profiles for lovastatin compared with placebo. The lovastatin arm did show a significant and considerable decrease in total serum cholesterol and serum low-density lipoprotein (LDL) levels compared with placebo, an expected result. This finding bolsters confidence in subject compliance. Given the results of this trial, it is concluded that if lovastatin were to lower the incidence of melanoma, it would appear not to be doing so by reversing atypia of precursor atypical nevi over the 6-month time frame studied. Further research into the pathogenesis of melanoma and in other potential chemopreventive agents is needed.

Published
2014

15. CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire

Author

Robert, Lidia, Tsoi, Jennifer, Wang, Xiaoyan, Emerson, Ryan, Homet, Blanca, Chodon, Thinle, Mok, Stephen, Huang, Rong Rong, Cochran, Alistair J, Comin-Anduix, Begoña, Koya, Richard C, Graeber, Thomas G, Robins, Harlan, and Ribas, Antoni

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Clinical Trials and Supportive Activities, Clinical Research, Adult, Aged, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, CTLA-4 Antigen, Cluster Analysis, Complementarity Determining Regions, Computational Biology, Female, Genetic Variation, Humans, Leukocytes, Mononuclear, Lymphocyte Count, Lymphocytes, Tumor-Infiltrating, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Receptors, Antigen, T-Cell, Receptors, Antigen, T-Cell, alpha-beta, Sequence Analysis, DNA, T-Lymphocytes, Cytotoxic, Treatment Outcome, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeTo evaluate the immunomodulatory effects of cytotoxic T-lymphocyte-associated protein 4 (CTLA4) blockade with tremelimumab in peripheral blood mononuclear cells (PBMC).Experimental designWe used next-generation sequencing to study the complementarity-determining region 3 (CDR3) from the rearranged T-cell receptor (TCR) variable beta (V-beta) in PBMCs of 21 patients, at baseline and 30 to 60 days after receiving tremelimumab.ResultsAfter receiving tremelimumab, there was a median of 30% increase in unique productive sequences of TCR V-beta CDR3 in 19 out of 21 patients, and a median decrease of 30% in only 2 out of 21 patients. These changes were significant for richness (P = 0.01) and for Shannon index diversity (P = 0.04). In comparison, serially collected PBMCs from four healthy donors did not show a significant change in TCR V-beta CDR3 diversity over 1 year. There was a significant difference in the total unique productive TCR V-beta CDR3 sequences between patients experiencing toxicity with tremelimumab compared with patients without toxicity (P = 0.05). No relevant differences were noted between clinical responders and nonresponders.ConclusionsCTLA4 blockade with tremelimumab diversifies the peripheral T-cell pool, representing a pharmacodynamic effect of how this class of antibodies modulates the human immune system.

Published
2014

16. COX‐2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors

Author

Escuin-Ordinas, Helena, Atefi, Mohammad, Fu, Yong, Cass, Ashley, Ng, Charles, Huang, Rong Rong, Yashar, Sharona, Comin-Anduix, Begonya, Avramis, Earl, Cochran, Alistair J, Marais, Richard, Lo, Roger S, Graeber, Thomas G, Herschman, Harvey R, and Ribas, Antoni

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, 5.1 Pharmaceuticals, Animals, Carcinoma, Squamous Cell, Celecoxib, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors, Female, Gene Expression Regulation, Neoplastic, Humans, Indoles, Keratoacanthoma, Melanoma, Mice, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Pyrazoles, Pyridones, Pyrimidinones, Skin Neoplasms, Sulfonamides, Vemurafenib, Squamous cell carcinomas, COX-2, celecoxib, vemurafenib, trametinib, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Keratoacanthomas (KAs) and cutaneous squamous cell carcinomas (cuSCCs) develop in 15-30% of patients with BRAF(V600E) metastatic melanoma treated with BRAF inhibitors (BRAFi). These lesions resemble mouse skin tumors induced by the two-stage DMBA/TPA skin carcinogenesis protocol; in this protocol BRAFi accelerates tumor induction. Since prior studies demonstrated cyclooxygenase 2 (COX-2) is necessary for DMBA/TPA tumor induction, we hypothesized that COX-2 inhibition might prevent BRAFi-accelerated skin tumors. Celecoxib, a COX-2 inhibitor, significantly delayed tumor acceleration by the BRAFi inhibitor PLX7420 and decreased tumor number by 90%. Tumor gene expression profiling demonstrated that celecoxib partially reversed the PLX4720-induced gene signature. In PDV cuSCC cells, vemurafenib (a clinically approved BRAFi) increased ERK phosphorylation and soft agar colony formation; both responses were greatly decreased by celecoxib. In clinical trials trametinib, a MEK inhibitor (MEKi) increases BRAFi therapy efficacy in BRAF(V600E) melanomas and reduces BRAFi-induced KA and cuSCC frequency. Trametinib also reduced vemurafenib-induced PDV soft agar colonies, but less efficiently than celecoxib. The trametinb/celecoxib combination was more effective than either inhibitor alone. In conclusion, celecoxib suppressed both BRAFi-accelerated skin tumors and soft-agar colonies, warranting its testing as a chemopreventive agent for non-melanoma skin lesions in patients treated with BRAFi alone or in combination with MEKi.

Published
2014

17. Letter Regarding Editorial by Samuel Zagarella

Author

Faries, Mark B., Ascierto, Paolo A., Blank, Christian, Cochran, Alistair J., Delman, Keith, Gyorki, David, Haanen, John, Hamid, Omid, Han, Dale, Karakousis, Giorgos, Kashani-Sabet, Mohammed, Leachman, Sancy, Moncrieff, Marc, Plasmeijer, Elsemieke, Enrico Testori, Alessandro Achille, Van Akkooi, Alexander, Wong, Sandra, and Zager, Jonathan S.

Published
2020
Full Text
View/download PDF

19. RT in situ PCR detection of MART-1 and TRP-2 mRNA in formalin-fixed, paraffin-embedded tissues of melanoma and nevi.

Author

Itakura, Eijun, Huang, Rong-Rong, Wen, Duan-Ren, Paul, Eberhard, Wünsch, Peter H, and Cochran, Alistair J

Subjects
MART-1, melanocytic neoplasms, melanoma, RT in situ PCR, tyrosinase-related protein-2
Abstract

Melanoma antigen recognized by T cells 1 (MART-1) and tyrosinase-related protein-2 (TRP-2) are two useful markers for immunohistochemical detection of melanocytic tumors. However, these markers may be passively acquired (phagocytosed) rather than actively synthesized. Reverse transcriptase in situ polymerase chain reaction (RT in situ PCR) can amplify even small amounts of specific mRNA in cells and therefore confirm the cellular source of a marker. We developed a one-step RT in situ PCR procedure in which Thermus thermophilus DNA polymerase synthesizes and amplifies cDNA from mRNA in a single reaction mixture. To examine its practicability and feasibility with formalin-fixed, paraffin-embedded (FFPE) tissue, we compared the results of one-step RT in situ PCR with those of immunohistochemistry (IHC). MART-1 mRNA was identified in the cytoplasm of lesional cells from 23/26 primary melanomas (92%), 9/9 metastatic melanomas (100%) and 5/6 nevi (83%). MART-1 epitope was detected by IHC in 23/24 primary melanomas (96%), 9/9 metastatic melanomas (100%) and 5/6 nevi (83%). TRP-2 mRNA was identified in the cytoplasm of lesional cells from 17/26 primary melanomas (65%), 6/9 metastatic melanomas (67%) and 4/6 nevi (67%). TRP-2 epitope was detected by IHC in 20/24 primary melanomas (83%), 9/9 metastatic melanomas (100%) and 4/6 nevi (67%). Both techniques detected MART-1 and TRP-2 in FFPE melanoma cell lines. Neither marker was detected in squamous cell carcinomas or basal cell carcinomas by RT in situ PCR or IHC. We conclude that the RT in situ PCR technique can be successfully applied to FFPE tissue to determine the cellular sources of gene expression observed by conventional PCR approaches.

Published
2008

21. Biopsy of the Sentinel Lymph Node

Author

Faries, Mark B., primary, Cochran, Alistair J., additional, McLemore, Michael, additional, Sondak, Vernon K., additional, Wong, Sandra, additional, and Thompson, John F., additional

Published
2019
Full Text
View/download PDF

22. Supplementary Tables 1 - 5 from Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy

Author

Ma, Chao, primary, Cheung, Ann F., primary, Chodon, Thinle, primary, Koya, Richard C., primary, Wu, Zhongqi, primary, Ng, Charles, primary, Avramis, Earl, primary, Cochran, Alistair J., primary, Witte, Owen N., primary, Baltimore, David, primary, Chmielowski, Bartosz, primary, Economou, James S., primary, Comin-Anduix, Begonya, primary, Ribas, Antoni, primary, and Heath, James R., primary

Published
2023
Full Text
View/download PDF

23. Data from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology

Author

Linden, Kenneth G., primary, Leachman, Sancy A., primary, Zager, Jonathan S., primary, Jakowatz, James G., primary, Viner, Jaye L., primary, McLaren, Christine E., primary, Barr, Ronald J., primary, Carpenter, Philip M., primary, Chen, Wen-Pin, primary, Elmets, Craig A., primary, Tangrea, Joseph A., primary, Lim, Sung-Jig, primary, Cochran, Alistair J., primary, and Meyskens, Frank L., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Materials and Methods from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology

Author

Linden, Kenneth G., primary, Leachman, Sancy A., primary, Zager, Jonathan S., primary, Jakowatz, James G., primary, Viner, Jaye L., primary, McLaren, Christine E., primary, Barr, Ronald J., primary, Carpenter, Philip M., primary, Chen, Wen-Pin, primary, Elmets, Craig A., primary, Tangrea, Joseph A., primary, Lim, Sung-Jig, primary, Cochran, Alistair J., primary, and Meyskens, Frank L., primary

Published
2023
Full Text
View/download PDF

25. Data from Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy

Author

Ma, Chao, primary, Cheung, Ann F., primary, Chodon, Thinle, primary, Koya, Richard C., primary, Wu, Zhongqi, primary, Ng, Charles, primary, Avramis, Earl, primary, Cochran, Alistair J., primary, Witte, Owen N., primary, Baltimore, David, primary, Chmielowski, Bartosz, primary, Economou, James S., primary, Comin-Anduix, Begonya, primary, Ribas, Antoni, primary, and Heath, James R., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figures 1 - 8 from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology

Author

Linden, Kenneth G., primary, Leachman, Sancy A., primary, Zager, Jonathan S., primary, Jakowatz, James G., primary, Viner, Jaye L., primary, McLaren, Christine E., primary, Barr, Ronald J., primary, Carpenter, Philip M., primary, Chen, Wen-Pin, primary, Elmets, Craig A., primary, Tangrea, Joseph A., primary, Lim, Sung-Jig, primary, Cochran, Alistair J., primary, and Meyskens, Frank L., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure Legends from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology

Author

Linden, Kenneth G., primary, Leachman, Sancy A., primary, Zager, Jonathan S., primary, Jakowatz, James G., primary, Viner, Jaye L., primary, McLaren, Christine E., primary, Barr, Ronald J., primary, Carpenter, Philip M., primary, Chen, Wen-Pin, primary, Elmets, Craig A., primary, Tangrea, Joseph A., primary, Lim, Sung-Jig, primary, Cochran, Alistair J., primary, and Meyskens, Frank L., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figures 1 - 8 from Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy

Author

Ma, Chao, primary, Cheung, Ann F., primary, Chodon, Thinle, primary, Koya, Richard C., primary, Wu, Zhongqi, primary, Ng, Charles, primary, Avramis, Earl, primary, Cochran, Alistair J., primary, Witte, Owen N., primary, Baltimore, David, primary, Chmielowski, Bartosz, primary, Economou, James S., primary, Comin-Anduix, Begonya, primary, Ribas, Antoni, primary, and Heath, James R., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Tables 1 - 2 from A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology

Author

Linden, Kenneth G., primary, Leachman, Sancy A., primary, Zager, Jonathan S., primary, Jakowatz, James G., primary, Viner, Jaye L., primary, McLaren, Christine E., primary, Barr, Ronald J., primary, Carpenter, Philip M., primary, Chen, Wen-Pin, primary, Elmets, Craig A., primary, Tangrea, Joseph A., primary, Lim, Sung-Jig, primary, Cochran, Alistair J., primary, and Meyskens, Frank L., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table S3 from A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab

Author

Nowicki, Theodore S., primary, Berent-Maoz, Beata, primary, Cheung-Lau, Gardenia, primary, Huang, Rong Rong, primary, Wang, Xiaoyan, primary, Tsoi, Jennifer, primary, Kaplan-Lefko, Paula, primary, Cabrera, Paula, primary, Tran, Justin, primary, Pang, Jia, primary, Macabali, Mignonette, primary, Garcilazo, Ivan Perez, primary, Carretero, Ignacio Baselga, primary, Kalbasi, Anusha, primary, Cochran, Alistair J., primary, Grasso, Catherine S., primary, Hu-Lieskovan, Siwen, primary, Chmielowski, Bartosz, primary, Comin-Anduix, Begoña, primary, Singh, Arun, primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Table S1 from Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma

Author

Ribas, Antoni, primary, Comin-Anduix, Begoña, primary, Chmielowski, Bartosz, primary, Jalil, Jason, primary, de la Rocha, Pilar, primary, McCannel, Tara A., primary, Ochoa, Maria Teresa, primary, Seja, Elizabeth, primary, Villanueva, Arturo, primary, Oseguera, Denise K., primary, Straatsma, Bradley R., primary, Cochran, Alistair J., primary, Glaspy, John A., primary, Hui, Liu, primary, Marincola, Francesco M., primary, Wang, Ena, primary, Economou, James S., primary, and Gomez-Navarro, Jesus, primary

Published
2023
Full Text
View/download PDF

34. Figures S1, S2, S3, S4, S5 from A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab

Author

Nowicki, Theodore S., primary, Berent-Maoz, Beata, primary, Cheung-Lau, Gardenia, primary, Huang, Rong Rong, primary, Wang, Xiaoyan, primary, Tsoi, Jennifer, primary, Kaplan-Lefko, Paula, primary, Cabrera, Paula, primary, Tran, Justin, primary, Pang, Jia, primary, Macabali, Mignonette, primary, Garcilazo, Ivan Perez, primary, Carretero, Ignacio Baselga, primary, Kalbasi, Anusha, primary, Cochran, Alistair J., primary, Grasso, Catherine S., primary, Hu-Lieskovan, Siwen, primary, Chmielowski, Bartosz, primary, Comin-Anduix, Begoña, primary, Singh, Arun, primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 9 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

Author

Chodon, Thinle, primary, Comin-Anduix, Begoña, primary, Chmielowski, Bartosz, primary, Koya, Richard C., primary, Wu, Zhongqi, primary, Auerbach, Martin, primary, Ng, Charles, primary, Avramis, Earl, primary, Seja, Elizabeth, primary, Villanueva, Arturo, primary, McCannel, Tara A., primary, Ishiyama, Akira, primary, Czernin, Johannes, primary, Radu, Caius G., primary, Wang, Xiaoyan, primary, Gjertson, David W., primary, Cochran, Alistair J., primary, Cornetta, Kenneth, primary, Wong, Deborah J.L., primary, Kaplan-Lefko, Paula, primary, Hamid, Omid, primary, Samlowski, Wolfram, primary, Cohen, Peter A., primary, Daniels, Gregory A., primary, Mukherji, Bijay, primary, Yang, Lili, primary, Zack, Jerome A., primary, Kohn, Donald B., primary, Heath, James R., primary, Glaspy, John A., primary, Witte, Owen N., primary, Baltimore, David, primary, Economou, James S., primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figures S1-S2 from Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade

Author

Ribas, Antoni, primary, Comin-Anduix, Begoña, primary, Economou, James S., primary, Donahue, Timothy R., primary, de la Rocha, Pilar, primary, Morris, Lilah F., primary, Jalil, Jason, primary, Dissette, Vivian B., primary, Shintaku, Itsushi Peter, primary, Glaspy, John A., primary, Gomez-Navarro, Jesus, primary, and Cochran, Alistair J., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Methods, Figure Legends, Table 1 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

Author

Chodon, Thinle, primary, Comin-Anduix, Begoña, primary, Chmielowski, Bartosz, primary, Koya, Richard C., primary, Wu, Zhongqi, primary, Auerbach, Martin, primary, Ng, Charles, primary, Avramis, Earl, primary, Seja, Elizabeth, primary, Villanueva, Arturo, primary, McCannel, Tara A., primary, Ishiyama, Akira, primary, Czernin, Johannes, primary, Radu, Caius G., primary, Wang, Xiaoyan, primary, Gjertson, David W., primary, Cochran, Alistair J., primary, Cornetta, Kenneth, primary, Wong, Deborah J.L., primary, Kaplan-Lefko, Paula, primary, Hamid, Omid, primary, Samlowski, Wolfram, primary, Cohen, Peter A., primary, Daniels, Gregory A., primary, Mukherji, Bijay, primary, Yang, Lili, primary, Zack, Jerome A., primary, Kohn, Donald B., primary, Heath, James R., primary, Glaspy, John A., primary, Witte, Owen N., primary, Baltimore, David, primary, Economou, James S., primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 1 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

Author

Chodon, Thinle, primary, Comin-Anduix, Begoña, primary, Chmielowski, Bartosz, primary, Koya, Richard C., primary, Wu, Zhongqi, primary, Auerbach, Martin, primary, Ng, Charles, primary, Avramis, Earl, primary, Seja, Elizabeth, primary, Villanueva, Arturo, primary, McCannel, Tara A., primary, Ishiyama, Akira, primary, Czernin, Johannes, primary, Radu, Caius G., primary, Wang, Xiaoyan, primary, Gjertson, David W., primary, Cochran, Alistair J., primary, Cornetta, Kenneth, primary, Wong, Deborah J.L., primary, Kaplan-Lefko, Paula, primary, Hamid, Omid, primary, Samlowski, Wolfram, primary, Cohen, Peter A., primary, Daniels, Gregory A., primary, Mukherji, Bijay, primary, Yang, Lili, primary, Zack, Jerome A., primary, Kohn, Donald B., primary, Heath, James R., primary, Glaspy, John A., primary, Witte, Owen N., primary, Baltimore, David, primary, Economou, James S., primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 8 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

Author

Chodon, Thinle, primary, Comin-Anduix, Begoña, primary, Chmielowski, Bartosz, primary, Koya, Richard C., primary, Wu, Zhongqi, primary, Auerbach, Martin, primary, Ng, Charles, primary, Avramis, Earl, primary, Seja, Elizabeth, primary, Villanueva, Arturo, primary, McCannel, Tara A., primary, Ishiyama, Akira, primary, Czernin, Johannes, primary, Radu, Caius G., primary, Wang, Xiaoyan, primary, Gjertson, David W., primary, Cochran, Alistair J., primary, Cornetta, Kenneth, primary, Wong, Deborah J.L., primary, Kaplan-Lefko, Paula, primary, Hamid, Omid, primary, Samlowski, Wolfram, primary, Cohen, Peter A., primary, Daniels, Gregory A., primary, Mukherji, Bijay, primary, Yang, Lili, primary, Zack, Jerome A., primary, Kohn, Donald B., primary, Heath, James R., primary, Glaspy, John A., primary, Witte, Owen N., primary, Baltimore, David, primary, Economou, James S., primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure 2 from CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire

Author

Robert, Lidia, primary, Tsoi, Jennifer, primary, Wang, Xiaoyan, primary, Emerson, Ryan, primary, Homet, Blanca, primary, Chodon, Thinle, primary, Mok, Stephen, primary, Huang, Rong Rong, primary, Cochran, Alistair J., primary, Comin-Anduix, Begoña, primary, Koya, Richard C., primary, Graeber, Thomas G., primary, Robins, Harlan, primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

41. Supplemental Figure Legends from A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab

Author

Nowicki, Theodore S., primary, Berent-Maoz, Beata, primary, Cheung-Lau, Gardenia, primary, Huang, Rong Rong, primary, Wang, Xiaoyan, primary, Tsoi, Jennifer, primary, Kaplan-Lefko, Paula, primary, Cabrera, Paula, primary, Tran, Justin, primary, Pang, Jia, primary, Macabali, Mignonette, primary, Garcilazo, Ivan Perez, primary, Carretero, Ignacio Baselga, primary, Kalbasi, Anusha, primary, Cochran, Alistair J., primary, Grasso, Catherine S., primary, Hu-Lieskovan, Siwen, primary, Chmielowski, Bartosz, primary, Comin-Anduix, Begoña, primary, Singh, Arun, primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 1 from CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire

Author

Robert, Lidia, primary, Tsoi, Jennifer, primary, Wang, Xiaoyan, primary, Emerson, Ryan, primary, Homet, Blanca, primary, Chodon, Thinle, primary, Mok, Stephen, primary, Huang, Rong Rong, primary, Cochran, Alistair J., primary, Comin-Anduix, Begoña, primary, Koya, Richard C., primary, Graeber, Thomas G., primary, Robins, Harlan, primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure Legends, Tables 1 - 3 from CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire

Author

Robert, Lidia, primary, Tsoi, Jennifer, primary, Wang, Xiaoyan, primary, Emerson, Ryan, primary, Homet, Blanca, primary, Chodon, Thinle, primary, Mok, Stephen, primary, Huang, Rong Rong, primary, Cochran, Alistair J., primary, Comin-Anduix, Begoña, primary, Koya, Richard C., primary, Graeber, Thomas G., primary, Robins, Harlan, primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 1 from CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans

Author

Huang, Rong Rong, primary, Jalil, Jason, primary, Economou, James S., primary, Chmielowski, Bartosz, primary, Koya, Richard C., primary, Mok, Stephen, primary, Sazegar, Hooman, primary, Seja, Elizabeth, primary, Villanueva, Arturo, primary, Gomez-Navarro, Jesus, primary, Glaspy, John A., primary, Cochran, Alistair J., primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure 3 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

Author

Chodon, Thinle, primary, Comin-Anduix, Begoña, primary, Chmielowski, Bartosz, primary, Koya, Richard C., primary, Wu, Zhongqi, primary, Auerbach, Martin, primary, Ng, Charles, primary, Avramis, Earl, primary, Seja, Elizabeth, primary, Villanueva, Arturo, primary, McCannel, Tara A., primary, Ishiyama, Akira, primary, Czernin, Johannes, primary, Radu, Caius G., primary, Wang, Xiaoyan, primary, Gjertson, David W., primary, Cochran, Alistair J., primary, Cornetta, Kenneth, primary, Wong, Deborah J.L., primary, Kaplan-Lefko, Paula, primary, Hamid, Omid, primary, Samlowski, Wolfram, primary, Cohen, Peter A., primary, Daniels, Gregory A., primary, Mukherji, Bijay, primary, Yang, Lili, primary, Zack, Jerome A., primary, Kohn, Donald B., primary, Heath, James R., primary, Glaspy, John A., primary, Witte, Owen N., primary, Baltimore, David, primary, Economou, James S., primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure 7 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

Author

Chodon, Thinle, primary, Comin-Anduix, Begoña, primary, Chmielowski, Bartosz, primary, Koya, Richard C., primary, Wu, Zhongqi, primary, Auerbach, Martin, primary, Ng, Charles, primary, Avramis, Earl, primary, Seja, Elizabeth, primary, Villanueva, Arturo, primary, McCannel, Tara A., primary, Ishiyama, Akira, primary, Czernin, Johannes, primary, Radu, Caius G., primary, Wang, Xiaoyan, primary, Gjertson, David W., primary, Cochran, Alistair J., primary, Cornetta, Kenneth, primary, Wong, Deborah J.L., primary, Kaplan-Lefko, Paula, primary, Hamid, Omid, primary, Samlowski, Wolfram, primary, Cohen, Peter A., primary, Daniels, Gregory A., primary, Mukherji, Bijay, primary, Yang, Lili, primary, Zack, Jerome A., primary, Kohn, Donald B., primary, Heath, James R., primary, Glaspy, John A., primary, Witte, Owen N., primary, Baltimore, David, primary, Economou, James S., primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 2 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

Author

Chodon, Thinle, primary, Comin-Anduix, Begoña, primary, Chmielowski, Bartosz, primary, Koya, Richard C., primary, Wu, Zhongqi, primary, Auerbach, Martin, primary, Ng, Charles, primary, Avramis, Earl, primary, Seja, Elizabeth, primary, Villanueva, Arturo, primary, McCannel, Tara A., primary, Ishiyama, Akira, primary, Czernin, Johannes, primary, Radu, Caius G., primary, Wang, Xiaoyan, primary, Gjertson, David W., primary, Cochran, Alistair J., primary, Cornetta, Kenneth, primary, Wong, Deborah J.L., primary, Kaplan-Lefko, Paula, primary, Hamid, Omid, primary, Samlowski, Wolfram, primary, Cohen, Peter A., primary, Daniels, Gregory A., primary, Mukherji, Bijay, primary, Yang, Lili, primary, Zack, Jerome A., primary, Kohn, Donald B., primary, Heath, James R., primary, Glaspy, John A., primary, Witte, Owen N., primary, Baltimore, David, primary, Economou, James S., primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure 6 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

Author

Chodon, Thinle, primary, Comin-Anduix, Begoña, primary, Chmielowski, Bartosz, primary, Koya, Richard C., primary, Wu, Zhongqi, primary, Auerbach, Martin, primary, Ng, Charles, primary, Avramis, Earl, primary, Seja, Elizabeth, primary, Villanueva, Arturo, primary, McCannel, Tara A., primary, Ishiyama, Akira, primary, Czernin, Johannes, primary, Radu, Caius G., primary, Wang, Xiaoyan, primary, Gjertson, David W., primary, Cochran, Alistair J., primary, Cornetta, Kenneth, primary, Wong, Deborah J.L., primary, Kaplan-Lefko, Paula, primary, Hamid, Omid, primary, Samlowski, Wolfram, primary, Cohen, Peter A., primary, Daniels, Gregory A., primary, Mukherji, Bijay, primary, Yang, Lili, primary, Zack, Jerome A., primary, Kohn, Donald B., primary, Heath, James R., primary, Glaspy, John A., primary, Witte, Owen N., primary, Baltimore, David, primary, Economou, James S., primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Methods from A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab

Author

Nowicki, Theodore S., primary, Berent-Maoz, Beata, primary, Cheung-Lau, Gardenia, primary, Huang, Rong Rong, primary, Wang, Xiaoyan, primary, Tsoi, Jennifer, primary, Kaplan-Lefko, Paula, primary, Cabrera, Paula, primary, Tran, Justin, primary, Pang, Jia, primary, Macabali, Mignonette, primary, Garcilazo, Ivan Perez, primary, Carretero, Ignacio Baselga, primary, Kalbasi, Anusha, primary, Cochran, Alistair J., primary, Grasso, Catherine S., primary, Hu-Lieskovan, Siwen, primary, Chmielowski, Bartosz, primary, Comin-Anduix, Begoña, primary, Singh, Arun, primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figure 4 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

Author

Chodon, Thinle, primary, Comin-Anduix, Begoña, primary, Chmielowski, Bartosz, primary, Koya, Richard C., primary, Wu, Zhongqi, primary, Auerbach, Martin, primary, Ng, Charles, primary, Avramis, Earl, primary, Seja, Elizabeth, primary, Villanueva, Arturo, primary, McCannel, Tara A., primary, Ishiyama, Akira, primary, Czernin, Johannes, primary, Radu, Caius G., primary, Wang, Xiaoyan, primary, Gjertson, David W., primary, Cochran, Alistair J., primary, Cornetta, Kenneth, primary, Wong, Deborah J.L., primary, Kaplan-Lefko, Paula, primary, Hamid, Omid, primary, Samlowski, Wolfram, primary, Cohen, Peter A., primary, Daniels, Gregory A., primary, Mukherji, Bijay, primary, Yang, Lili, primary, Zack, Jerome A., primary, Kohn, Donald B., primary, Heath, James R., primary, Glaspy, John A., primary, Witte, Owen N., primary, Baltimore, David, primary, Economou, James S., primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results